FR2944437B1 - Utilisation d'inhibiteurs de l'expression d'hif 1 alpha pour proteger la peau des dommages deleteres induits par le rayonnement uva - Google Patents

Utilisation d'inhibiteurs de l'expression d'hif 1 alpha pour proteger la peau des dommages deleteres induits par le rayonnement uva

Info

Publication number
FR2944437B1
FR2944437B1 FR0901853A FR0901853A FR2944437B1 FR 2944437 B1 FR2944437 B1 FR 2944437B1 FR 0901853 A FR0901853 A FR 0901853A FR 0901853 A FR0901853 A FR 0901853A FR 2944437 B1 FR2944437 B1 FR 2944437B1
Authority
FR
France
Prior art keywords
uva radiation
skin
hif
protect
damage induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0901853A
Other languages
English (en)
Other versions
FR2944437A1 (fr
Inventor
Francoise Bernerd
Jean Krutmann
Claire Marionnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to FR0901853A priority Critical patent/FR2944437B1/fr
Publication of FR2944437A1 publication Critical patent/FR2944437A1/fr
Application granted granted Critical
Publication of FR2944437B1 publication Critical patent/FR2944437B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Abstract

La présente invention concerne différentes méthodes de protection ou de prévention des effets délétères cosmétiques induits par le rayonnement UVA sur la peau d'un sujet, comprenant l'administration d'un agent capable d'inhiber le facteur de transcription HIF1α ou son expression. La présente invention concerne également des applications thérapeutiques d'un agent capable d'inhiber le facteur de transcription HIF1α ou son expression, dans la photoprotection de la peau contre le rayonnement UVA. Enfin, l'invention a également trait à des procédés pour cribler des molécules susceptibles d'assurer la protection et/ou la prévention des dommages induits par le rayonnement UVA ainsi que des méthodes d'évaluation de l'efficacité de molécules dans leur action protectrice de la peau à l'encontre du rayonnement UVA.
FR0901853A 2009-04-16 2009-04-16 Utilisation d'inhibiteurs de l'expression d'hif 1 alpha pour proteger la peau des dommages deleteres induits par le rayonnement uva Expired - Fee Related FR2944437B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0901853A FR2944437B1 (fr) 2009-04-16 2009-04-16 Utilisation d'inhibiteurs de l'expression d'hif 1 alpha pour proteger la peau des dommages deleteres induits par le rayonnement uva

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0901853A FR2944437B1 (fr) 2009-04-16 2009-04-16 Utilisation d'inhibiteurs de l'expression d'hif 1 alpha pour proteger la peau des dommages deleteres induits par le rayonnement uva

Publications (2)

Publication Number Publication Date
FR2944437A1 FR2944437A1 (fr) 2010-10-22
FR2944437B1 true FR2944437B1 (fr) 2013-05-10

Family

ID=41478703

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0901853A Expired - Fee Related FR2944437B1 (fr) 2009-04-16 2009-04-16 Utilisation d'inhibiteurs de l'expression d'hif 1 alpha pour proteger la peau des dommages deleteres induits par le rayonnement uva

Country Status (1)

Country Link
FR (1) FR2944437B1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2987057B1 (fr) * 2012-02-17 2015-09-04 Oreal Genes bio-marqueurs pour selectionner et evaluer l'efficacite de protection d'un produit solaire face a des uva longs
FR2993282B1 (fr) * 2012-07-13 2017-11-10 Expanscience Lab Procede d'identification de marqueurs moleculaires de la peau d'enfant
CN113842383A (zh) * 2021-09-26 2021-12-28 中国科学院昆明植物研究所 维采宁-1在制备抗uvb辐射制剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787996B1 (fr) * 1998-12-30 2002-05-10 Dior Christian Parfums Composition cosmetique ou dermatologique contenant un actif stimulant la synthese de la proteine hsp 32 dans la peau et methode de traitement cosmetique
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
FR2815861B1 (fr) * 2000-10-26 2003-02-28 Oreal Utilisation de l'association d'au moins un carotenoide et d'au moins un isoflavonoide pour traiter les signes cutanes du vieillissement
FR2820974B1 (fr) * 2001-02-21 2004-02-13 Pharmascience Lab Composition topique comprenant une solution vraie contenant un derive de chromane ou de chromene, son procede de preparation et son utilisation cosmetique et therapeutique
ITRM20010600A1 (it) * 2001-10-04 2003-04-04 Brane Tech S R L Composti flavonoidici capaci di modificare lo stato fisico e/o dinamico di membrane biologiche e di stimolare la sintesi endogena di protein
WO2004042024A2 (fr) * 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania Compositions et procedes destines a l'inhibition par arnsi des hif-1 alpha
DE10259966A1 (de) * 2002-12-15 2004-07-08 Henkel Kgaa Kosmetische oder pharmazeutische Zubereitung zur Verbesserung der Sauerstoffaufnahme bei Menschen oder Tieren
FR2854243A1 (fr) * 2003-04-24 2004-10-29 Oreal Procede de determination d'etats pre-alopeciques et/ou d'atteintes cutanees au moyen d'un marqueur predictif: hif-1(hypoxia inducible factor-1)
WO2005035759A2 (fr) * 2003-08-20 2005-04-21 Sirna Therapeutics, Inc. Inhibition de l'expression de genes du facteur 1 induit par l'hypoxie (hif-1), dont la mediation est assuree par une interference arn, au moyen d'acide nucleique interferent court (ansi)
EP1537789B1 (fr) * 2003-12-04 2006-09-27 Cognis IP Management GmbH Composition pour application orale ou cosmétique
EP1748080A3 (fr) * 2005-03-11 2007-04-11 Epiontis GmbH L'ADN spécifique pour la caractérisation epigénétique de cellules et tissus
WO2007022412A2 (fr) * 2005-08-18 2007-02-22 The General Hospital Corporation Therapie combinee pour prevenir l'angiogenese
KR100759389B1 (ko) * 2005-10-10 2007-09-19 한국생명공학연구원 803번 아스파라진 잔기가 수화된 ＨＩＦ-1α를 특이적으로인식하는 단일클론항체 및 항원 펩티드

Also Published As

Publication number Publication date
FR2944437A1 (fr) 2010-10-22

Similar Documents

Publication Publication Date Title
EP3718560A3 (fr) Inhibiteurs de kinases dépendant de la cycline et leurs procédés d'utilisation
WO2009094172A3 (fr) Peptides protecteurs de tissu et analogues peptidiques pour la prévention et le traitement de maladies et de troubles associés à un endommagement tissulaire
WO2009017104A1 (fr) Agent de protection contre une lésion de tissu biologique provoquée par un rayonnement dans le proche infrarouge, et produit comprenant l'agent
WO2012107550A3 (fr) Principe actif dérivé de la biotechnologie, dans des compositions cosmétiques pour protéger la peau de lésions induites ou produites par des rayonnements infrarouges
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
EA200702510A1 (ru) Способы защиты от апоптоза с применением липопептидов
WO2012139081A3 (fr) Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2
WO2004089407A3 (fr) Immunomodulateurs zwitterioniques destines au traitement de l'asthme et des allergies
SV2009003283A (es) Inhibidores de la actividad de la akt
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
JO3358B1 (ar) معالجات حساسية العيون
BR112014012463A2 (pt) agente protetor para ceratoconjuntiva ou agente supressor para distúrbio ceratoconjuntival
WO2010009405A3 (fr) Agents nitroxyde ciblés
CY1110970T1 (el) Μεθοδος και διαταξη για την προστασια του καπνου
WO2007130725A3 (fr) Utilisation de hmgb1 en protection contre les lésions de reperfusion de l'ischémie
WO2007105203A3 (fr) Procede et composition pour la protection du tissu neuronal de degats induits par des niveaux eleves de glutamate
WO2014114888A3 (fr) Système de protection alternatif contre les uv et radicaux libres
BRPI0512183A (pt) preparações cosméticas ou dermatológicas eficazes para proteção contra
FR2944437B1 (fr) Utilisation d'inhibiteurs de l'expression d'hif 1 alpha pour proteger la peau des dommages deleteres induits par le rayonnement uva
WO2011125039A3 (fr) Utilisation cosmétique du géranylgéranyl-2-propanol
WO2010015965A3 (fr) Procédés et compositions de traitement d'un dommage neuronal et de modulation de canaux potentiels de récepteurs transitoires
WO2006035445A3 (fr) Procedes pour traiter des pathologies associees a un stress oxydatif
WO2012033368A3 (fr) Composition pour la peau contenant un extrait de prunus mume, en application externe
FR2963775B1 (fr) Dispositif de protection et ou de confinement des surfaces immergees et plus particulierement des coques de navires
WO2007128564A3 (fr) Utilisation d'un composé présentant une activité rankl

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20211205